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Abstract.
Background: Sleep problems are among the most common non-motor symptoms of Parkinson’s disease (PD). The PD Sleep
Scale 2nd version (PDSS-2) improved the original PDSS by adding more items on different aspects of sleep problems, making
it a more robust tool to evaluate the severity of sleep disturbances. However, previous studies on deep brain stimulation (DBS)
have not used the PDSS-2.
Objective: To determine if the PDSS-2 could detect improvement reliably in sleep problems after bilateral subthalamic nucleus
DBS for PD.
Methods: In this prospective study, 25 consecutive patients undergoing DBS implantation were enrolled. Patients were examined
twice: 1 week prior to the DBS implantation (baseline) and 12 months postoperatively. Severity of PD symptoms were assessed
by the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) and the Non-Motor Symptoms Scale (NMSS).
Presence and severity of sleep disturbances were specifically measured by PDSS-2.
Results: Total score of MDS-UPDRS improved from 81 (median, interquartile-range: 63–103) to 55 points (median, IQR:
46–75, p < 0.001). Health-related quality of life, measured by PDQ-39, also improved from 29 (IQR: 18–40) to 15 (IQR: 9–28)
points (p = 0.002). Most domains of NMSS also improved. At baseline 13 patients reported sleep problems, but 1 year after DBS
implantation only 3 did (p = 0.012). Although only 6 out of 15 items showed a significant decrease after DBS implantation, the
total score of PDSS-2 decreased from 24 (IQR: 17–32) to 10 (IQR: 7–18) points (P < 0.001).
Conclusions: Based on our results, PDSS-2 can detect improvements in sleep quality reliably after DBS implantation.
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INTRODUCTION
Recently the non-motor symptoms (NMS) of
Parkinson’s disease (PD) have been increasingly rec-
ognized as a major burden of quality of life [1, 2].
Among the NMS, sleep-related problems are the most
important and troublesome. Although sleep problems
can be present in up to 90% of PD patients, only a few
study focused on the outcome of different therapeutic
options to improve sleep quality.
Deep brain stimulation (DBS) of the subthalamic
nucleus (STN) is a well-established therapy for patients
with PD having advanced motor complications.
Previous electrophysiological and patient-reported
outcome-based studies demonstrated the beneficial
effect of STN DBS on sleep quality in PD [3–6].
Because sleep-related problems are certainly mul-
ticausal, instruments capable of measuring most
domains of sleep-disturbances are needed in the clin-
ical practice. Based on the systematic review and
evaluation of sleep-related rating scales by the Move-
ment Disorders Society Task Force [7], only a few
scales were found to be appropriate for the PD pop-
ulation. The original Parkinson’s Disease Sleep Scale
(PDSS) [8] was published in 2002, and it had 15 visual
analogue scale-based items. It was one of the first
sleep scales designed specifically for PD. Higher val-
ues on PDSS indicate a better sleep quality. Although
the application of PDSS was recommended by the
MDS Task Force, they identified some weaknesses of
the scale including the inability to specifically iden-
tify and measure the presence and severity of sleep
apnea, rapid eye movements sleep behavioral sleep dis-
order (RBS) and restless legs syndrome RLS-related
symptoms. To overcome these disadvantages, a new
scale, the Parkinson’s Disease Sleep Scale 2nd version
(PDSS-2), was developed and published in 2011 [9].
The PDSS-2 scale is composed of 15 items evaluat-
ing three domains. Each item has a 5-point Likert-type
scale ranging from 0: “Never” to 4: “Very often”
(except for item 1 which is reversed). Each domain
consists of clusters of five questions evaluating motor
symptoms at night, PD symptoms at night and dis-
turbed sleep [9]. The sum of the 15 responses gives
the total score of PDSS-2 with the maximum value of
60 points and higher scores meaning more nocturnal
disturbance. The reliability, precision and test-retest
validity of PDSS-2 is good [9, 10], making it suitable
for measuring changes over a longer period of time.
PDSS-2 is thought to have better clinimetric proper-
ties and responsiveness to changes in sleep problems
than the original PDSS [11].
Despite its advantages over PDSS, the assessment
of sleep quality before and after bilateral STN DBS
with the PDSS-2 has not been reported in the literature;
thus, the responsiveness of the PDSS-2 to DBS treat-
ment is unknown. The objective of the present study
was to analyze how bilateral subthalamic deep brain
stimulation therapy can change sleep disturbances as
assessed by the newly developed PDSS-2 and the
non-motor section of the Movement Disorders Society-
sponsored Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS).
MATERIALS AND METHODS
Patients
In this prospective study, 25 consecutive patients
undergoing bilateral subthalamic deep brain stimula-
tion at the University of Pe´cs were enrolled. All patients
fulfilled the UK Brain Bank criteria for PD [12].
Each subject gave written informed consent in accor-
dance with the ethical approval of the Regional Ethical
Board (3617.316-24983/KK41/2009). Each patient
was examined by a neurologist specialized in move-
ment disorders.
Because the presence of minor or major neurocogni-
tive disorder was a contraindication for DBS surgery,
such patients were not included in this study [13]. Pres-
ence of dementia was defined as either achieving ≤125
points on the Hungarian validated version of the Mattis
Dementia Rating Scale [14] and/or ≤22 points on the
Montreal Cognitive Assessment [15] and/or fulfilling
the criteria of dementia according to the DSM-IV-TR.
Patients were evaluated in ON state while receiv-
ing their usual antiparkinsonian and other medications.
Subsequently, levodopa equivalent dosage calculations
were performed [16].
Rating scales utilized in the study
Patients were examined twice: 1 week prior to the
DBS implantation (baseline) and 12 months postopera-
tively. Severity of PD symptoms was globally assessed
by the Hungarian validated version of the MDS-
UPDRS [17]. The recently published MDS-UPDRS is
a validated scale to assess non-motor aspects (Part 1)
and motor aspects (Part 2) of experiences of daily
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living, motor examination (Part 3) and motor compli-
cations (Part 4) [18]. Included in the non-motor part,
MDS-UPDRS has two items evaluating the presence
and severity of nighttime sleep problems (item 1.17)
and daytime sleepiness (item 1.18). These two items
serve as a screening tool for sleep disturbances and day-
time sleepiness [19]. As a part of the MDS-UPDRS, the
Hoehn-Yahr Scale was also taken to detect the overall
severity of PD. Besides, we also applied the Clinical
Global Impression – Severity scale (CGI-S) to evalu-
ate the overall illness severity on a 7-item Likert-type
scale: 1: normal, not at all ill; 2: borderline ill; 3: mildly
ill; 4: moderately ill; 5: markedly ill; 6: severely ill; or
7: extremely ill.
To assess non-motor symptoms globally, the Non-
Motor Symptoms Scale (NMSS) was also included.
This scale is obtained by trained professionals and
capable of simultaneously capturing the severity and
frequency of nine non-motor domains typical for PD.
Besides sleep, NMSS also evaluates cardiovascular,
cognitive, mood, hallucinatory, gastrointestinal, uri-
nary and sexual symptoms.
Presence and severity of sleep disturbances were
specifically measured by PDSS-2. The threshold indi-
cating sleep problems is 11 points for the Hungarian
version of PDSS-2 [20]. Meantime, daytime sleepiness
was assessed by the Epworth Sleepiness Scale [21]
with the cutoff value of 8 points [20, 22].
As part of the neuropsychological domain, depres-
sion (Beck and Montgomery Depression Scales) and
cognitive performance (Montreal Cognitive Assess-
ment [15], Mattis Dementia Rating Scale [14] and
Addenbrook Cognitive Examination [14]) were also
examined. Health-related quality of life was measured
by the Hungarian validated version of PDQ-39 [23].
Statistical analysis
All statistical analyses were carried out using the
IBM SPSS software package (version 22.0.1, IBM
Inc, Armonk, NY, USA). Because data from these
scales were ordinal, non-parametric tests were applied.
For description of the data, medians with interquar-
tile range (IQR: 25th-75th percentile) were calculated.
Wilcoxon signed rank test was applied for the com-
parison of baseline and follow-up values. To detect
which item of PDSS-2 has changed significantly, we
also used Bonferroni correction. For dichotomous vari-
ables (e.g., presence or absence of sleep-problems,
usage of levodopa, etc.) McNemar test, and for cate-
gorical variables Chi-square tests were used. Statistical
significance level was set at 5%.
RESULTS
Demographic and PD-related clinical data
The subject population consisted of 25 non-
demented PD patients (18 males, age: 55.9 ± 8.7 years,
disease duration: 11.0 ± 4.8 years). Nine patients had
rigid-akinetic, 6 had tremor-dominant and 10 had
mixed-type of PD. Hoehn-Yahr staging, medication
usage and levodopa equivalent dosages are demon-
strated in Table 1.
Severity of PD
While the antiparkinsonian medication was sig-
nificantly reduced from 814 mg (median, IQR:
564–914 mg) to 420 mg (IQR: 250–594 mg,p = 0.001),
the total score of MDS-UPDRS improved from 81
(median, IQR: 63–103 points) to 55 points (median,
IQR: 46–75 points, p < 0.001). Besides, all domains
of MDS-UPDRS also improved 12 months after DBS
implantation (Table 1). Although the HY staging
showed improvement, it did not reach the level of sta-
tistical significance (p = 0.095). However, significantly
more patients (9/25) reported either no or borderline
severity of PD after treatment compared to baseline
based on the CGI-S scale (3/25, p = 0.047, Chi-square
test).
Health-related quality of life also improved from
29 (IQR: 18–40) to 15 (IQR: 9–28) points (p = 0.002)
measured by the PDQ-39 Summary Index.
Non-motor symptoms
With the exception of hallucinatory symptoms and
sexual dysfunction, all domains of NMSS improved
after DBS treatment. The total score of NMSS
decreased from 68 (IQR: 46–85) to 40 points (IQR:
16–52, p = 0.001), whereas the Sleep domain of NMSS
improved from 19 (IQR: 14–27) to 9 points (IQR: 6–16,
p = 0.002, Table 1).
At baseline, 13 patients reported sleep problems (i.e.,
a total score of PDSS-2 ≥11 points), but 1 year after
the DBS implantation only 3 did (p = 0.012, McNe-
mar test). Simultaneously, the total score of PDSS-2
decreased from 24 (IQR: 17–32) to 10 (IQR: 7–18)
points (P < 0.001). Although all domains of the PDSS-
2 improved, only 6 items showed a significant decrease
after DBS implantation. “Bed sleep quality”, “Rest-
lessness of legs and arms at night”, “Urge to move legs
and arms at night”, “Uncomfortable and immobility at
night”, “Muscle cramps in arms and legs” and “Tremor
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on waking” items had significant improvement after
Bonferroni correction (Table 2). This improvement in
sleep quality was also captured by the MDS-UPDRS
item 1.7 (“Sleep problems”, Table 2).
Before DBS implantation, 15 patients reported day-
time sleepiness (i.e., total score of ESS ≥8 points),
which decreased to 9 patients 1 year after the operation
(p = 0.032, McNemar test). Meanwhile, the total score
of ESS improved from 9 (IQR: 6–13) to 5 (IQR: 4–11)
points (P = 0.003, Table 1). However, we detected only
a trend for improvement on item 1.8 (“Daytime sleepi-
ness”) of the MDS-UPDRS.
Both depression-measuring tools (BDI and
MADRS) demonstrated a significant improvement in
depressive symptoms; whereas, the neurocognitive
performance on neuropsychological tests (MDRS,
ACE and MOCA) did not change (Table 1).
DISCUSSION
The aim of the present study was to identify the
beneficiary effects of bilateral subthalamic deep brain
stimulation on sleep quality by the utilization of the
recently developed PDSS-2. As far as the authors are
aware, this is the first prospective study utilizing the
PDSS-2 and MDS-UPDRS scales to assess the longitu-
dinal changes in sleep disturbances. Since the PDSS-2
has distinctive items on different aspects of sleep dis-
turbances specific for PD, we were able to analyze what
components of sleep responded to DBS therapy.
Fulfilling our expectations, most non-motor symp-
toms (including mood, gastrointestinal, urinary,
cardiovascular and sleep) improved by STN DBS
according to the subscales of NMSS, MDS-UPDRS,
BDI and MADRS scales. Not only the number of
patients reporting clinically relevant sleep problems
decreased, but also the general sleep quality measured
by both Sleep section of the NMSS and the total score
of PDSS-2 improved.
The analysis of individual components of PDSS-2
revealed that only a few distinctive components of
sleep contributed to the observed improvement in sleep
quality. According to our data, RLS-related problems
(items 4 and 5: “Restlessness of legs and arms at night”
and “Urge to move legs and arms”), some nocturnal
OFF symptoms (items 9 and 11: “Uncomfortable and
immobility at night” and “Muscle cramps in arms and
legs”), tremor on waking (item 13) and general sleep
quality (item 1) improved significantly after STN DBS
therapy.
Previously, only a few studies utilized the
MDS-UPDRS to reveal the changes associated with
STN DBS. We identified a single study (Pubmed
search, keywords: MDS-UPDRS and DBS, assessed
on January 4, 2015) to determine if the MDS-UPDRS
could detect improvement in both motor and non-
motor symptoms after bilateral STN DBS for PD [24].
Although the authors concluded that all sections of
MDS-UPDRS improved 6 months after DBS implan-
tation, they did not find any improvement in item 1.7,
“Sleep problems”. Conversely, our study showed a
significant improvement in “Sleep problems” and a
trend for improvement in “Daytime Sleepiness” items
of MDS-UPDRS after Bonferroni correction. These
incongruent results might be due to methodological
discrepancies (20 patients vs. 25 patients, 6-month
vs. 12-month follow-up, parametric vs. non-parametric
tests). Probably because of the longer follow-up time,
we also experienced a more robust improvement in
Part 1 (5 points –median vs. 3.1 points –mean) of the
MDS-UPDRS.
To our knowledge, previous DBS studies have not
used the MDS-UPDRS and PDSS-2 at baseline and
post-DBS to track clinical symptoms. Although our
sample size was small, the degree of improvement
in motor symptoms, as a result of STN DBS in our
study, was similar to the improvement reported in a
large randomized trial of DBS that used the original
UPDRS [25, 26]. Although the clinimetric properties
of PDSS differ from those of PDSS-2 (15 visual ana-
logue scales vs. 15 Likert-type scales grouping into 3
major domains, higher values on PDSS represent a
better sleep quality vs. lower numbers mean a bet-
ter sleep quality on PDSS-2), we can compare their
responsiveness to STN DBS. Hjort et al. demonstrated
a 31.9% improvement (from 79.8 to 105.3 points on
PDSS) in 10 PD patients who underwent DBS implan-
tation. Chahine et al. analyzed 17 patients (12 receiving
unilateral and 5 bilateral DBS) 6 months after surgery
and reported a 30.5% improvement (from 94.2 to 122.9
points on PDSS) [6]. On the contrary, one article (avail-
able only in Chinese) did not report any significant
improvement on PDSS 1 year after the operation [27].
Despite the above mentioned discrepancies between
the PDSS and PDSS-2, we measured a comparable
improvement in sleep quality (58.3%, from 24 to 10
points, median values, p < 0.001).
CONCLUSIONS
Subthalamic deep brain stimulation not only can
decrease the number of patients reporting clinically
relevant sleep problems but also improve the general
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sleep quality. This improvement can be consistently
demonstrated by the PDSS-2, NMSS and the MDS-
UPDRS. Besides sleep, most domains of non-motor
symptoms and the health-related quality of life can be
improved by DBS therapy.
The PDSS-2 has some advantages over the origi-
nal PDSS in that it more comprehensively assesses
the different aspects of sleep problems specific for
PD. Because our results suggest that the PDSS-2 can
reliably detect the sleep-related changes after DBS,
we recommend that the PDSS-2 should be utilized in
future DBS studies.
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